GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY27 results · Apr–Jun 2026
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹938.44 crore (up 16.6% from Q1 FY26) and net profit of ₹237.18 crore (up 15.7% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 938.44 | 805.17 | +16.6% | 995.30 | −5.7% |
| Other income | 43.76 | 43.72 | +0.1% | 35.95 | +21.7% |
| Total income | 982.20 | 848.89 | +15.7% | 1,031.25 | −4.8% |
| Profit before tax | 322.45 | 278.98 | +15.6% | 373.10 | −13.6% |
| Net profit for the period | 237.18 | 205.01 | +15.7% | 277.86 | −14.6% |
| EPS, basic (₹) | 14.00 | 12.10 | +15.7% | 16.40 | −14.6% |
| Net margin (%) | 25.3 | 25.5 | 27.9 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 924.42 | 804.83 | +14.9% | 989.15 | −6.5% |
| Other income | 61.63 | 43.76 | +40.8% | 35.71 | +72.6% |
| Total income | 986.05 | 848.59 | +16.2% | 1,024.86 | −3.8% |
| Profit before tax | 337.98 | 278.57 | +21.3% | 369.12 | −8.4% |
| Net profit for the period | 253.33 | 204.70 | +23.8% | 274.94 | −7.9% |
| EPS, basic (₹) | 14.95 | 12.08 | +23.8% | 16.23 | −7.9% |
| Net margin (%) | 27.4 | 25.4 | 27.8 |
Consolidated
- Filed with BSE
- 03 Aug 2026, 20:35 IST
- Board meeting
- 03 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Aug 2026, 20:35 IST
- Board meeting
- 03 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE